Stock Details
MRK is Merck & Co., Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 89.50$. Average daily volumn in 3 months 12.53M. Market cap 233.71B

Stock symbol : MRK. Exchange : NYSE. Currency : USD
Lastest price : 92.42$. Total volume : 10.84M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Merck & Co., Inc. (MRK)
Last Price

Previous Close91.17
Day Range90.39-92.49
Bid91.66 x 1.4k
Ask92.48 x 800
Average Volume12.53M
Market Cap233.71B
52 Week Range70.89-95.72
Trailing P/E16.86
Foward P/E12.51
Dividend (Yield %)3.03%
Ex-Dividend Date2022-06-14

Financial Details

According to Merck & Co., Inc.'s financial reports the company's revenue in 2021 were 48.7B an increase( +17.07%) over the years 2020 revenue that were of 41.52B. In 2021 the company's total earnings were 13.05B while total earnings in 2020 were 7.07B( +85.71%).

Loading ...


Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuti... cals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Market Cap:
Total Assets:
Total Cash:

News about "Merck & Co., Inc."


This Acquisition Could Make Merck a Scorching-Hot Buy

Source from : The Motley Fool - 3 days ago

According to reports, Merck is looking at potentially acquiring Seagen. Seagen is a biotech focused on developing innovative treatments for cancer. The deal could help both companies become bigger and ...See details»

Merck & Co. Inc. (NYSE: MRK) Share Price Rose Recently, Although Trouble Is Still On The Horizon

Source from : stocksregister - 3 days ago

Merck & Co. Inc. (NYSE:MRK) traded at $92.56 at last check on Wednesday, June 29, made an upward move of 0.73% on its previous dayโ€™s price. Looking at the stock we see that its previous close was $91.See details»


Wedge Capital Management L L P NC Decreases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Source from : Defense World - 6 days ago

Wedge Capital Management L L P NC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK โ€“ Get Rating) by 2.9% during the first quarter, according to the company in its most recent disclosure ...See details»

Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?

Source from : YAHOO!Finance - 1 days ago

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Merck (MRK) been one of those stocks this year? A quick ...See details»


Why Call Traders Should Consider Merck Stock

Source from : - 4 days ago

Now looks like an ideal time initiate a long position on Merck stock Merck & Co., Inc.'s (NYSE:MRK) recent breakout above the $88 level took out both its 2021 and 2000 highs. Outperforming with 22.1% ...See details»


WEConnect International Named Merck a 2022 Platinum Top Global Supplier, Diversity & Inclusion Champion

Source from : CSR Wire - 1 days ago

We are thrilled to announce that WEConnect International has named us a 2022 Platinum Top Global Supplier, Diversity & Inclusion Champion!See details»


8 Analysts Have This to Say About Merck & Co

Source from : Business Insider - 5 days ago

These 8 analysts have an average price target of $96.25 versus the current price of Merck & Co at $95.01, implying upside. Below is a summary of how these 8 analysts rated Merck & ...See details»


Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28

Source from : Joplin Globe - 3 days ago

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on ...See details»

3 Reasons Why Merck (MRK) Is a Great Growth Stock

Source from : YAHOO!Finance - 3 days ago

Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks ...See details»


Seagen Would Be A Great Fit For Merck

Source from : Seeking Alpha - 5 days ago

While I would not be a buyer at current levels on a standalone basis, Seagen is a great company with a strong revenue base and great long-term growth prospects, and I think that Merck would be ...See details»


Merck launches Digital Sciences Studio for tech-driven startups

Source from : Seeking Alpha - 3 days ago

Merck (MRK) said it launched Merck Digital Sciences Studio ((MDSS)) to generate technologies for drug discovery and development.The Kenilworth, N.J.-based company ...See details»

Merckโ€™s Interest in Seagen is Mounting; Now What?

Source from : Nasdaq - 8 days ago

J ust days ago, biotech company Seagen jumped after reports emerged that Merck was interested in buying the company. Now, the company gained another 3.5% in pre-market trading on ...See details»


Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Companyโ€™s Investigational Pneumococcal Conjugate Vaccine for Adults

Source from : Joplin Globe - 11 days ago

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of positive results from the Phase 1/2 study, V116-001, evaluating the safety, tolerability and ...See details»

The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J

Source from : Nasdaq - 1 days ago announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...See details»